Company Overview - As of June 30, 2024, Mega Genomics has conducted over 21 million genetic tests since its establishment in 2016, averaging over 400,000 tests per month in the first half of 2024[8]. - The company has developed 107 commercialized testing solutions for consumer genetic testing and cancer screening, with 90 of these services being independently developed[8]. - Mega Genomics is recognized as the largest consumer genetic testing platform in China based on cumulative testing volume as of December 31, 2021[8]. - The company offers a range of popular testing services, including brain health assessment, nutritional absorption capability assessment, Parkinson's disease risk assessment, and comprehensive cancer risk assessment[8]. Research and Development - The company is focused on expanding its market presence and enhancing its product offerings through internal R&D and collaborations with third-party partners[8]. - The R&D strategy is market-oriented, focusing on expanding testing technology platforms and services based on industry trends and market demands[15]. - The company has a strong internal R&D team, with approximately 65% of its members holding master's degrees or higher from prestigious institutions[17]. - The company plans to enhance its research and development capabilities by recruiting more professionals and collaborating with renowned academic and medical institutions[30]. Product Development and Registration - The ApoE gene testing kit, utilizing blood nucleic acid non-extraction technology, is expected to be registered by the NMPA in the second half of 2024[11]. - The folate metabolism assessment kit aims to guide pregnant women in folate supplementation and has also been submitted for NMPA registration, expected in the second half of 2024[12]. - The Alzheimer's disease screening kit is based on plasma miRNA biomarkers and is in collaboration with multiple hospitals for clinical validation, with a registration expected by 2025[13]. - The colorectal cancer screening kit is utilizing plasma DNA methylation markers, with over 1,500 samples used for biomarker selection, and is expected to achieve registration by 2025[14]. - The gastric cancer screening kit is also based on plasma DNA methylation markers, with similar development and registration timelines as the colorectal cancer kit[14]. - The BRCA1/BRCA2 gene mutation testing kit has completed formulation development and established a database of tens of thousands of mutation sites[15]. - The company has received product registration certificates for fecal occult blood and transferrin testing kits, which are now in mass production[15]. - The company is in the process of IVD registration for several products, including the ApoE gene testing kit and colorectal cancer screening kit, which are currently in the registration phase[21]. Financial Performance - For the six months ended June 30, 2024, the company achieved total revenue of RMB 107.3 million, an increase of RMB 8.4 million or 8.5% compared to RMB 98.9 million for the same period in 2023[25]. - Revenue from consumer-grade genetic testing services and cancer screening services for the six months ended June 30, 2024, was RMB 104.4 million and RMB 2.9 million, respectively[25]. - Gross profit for the period was RMB 69,618 thousand, up 6.6% from RMB 65,299 thousand in the previous year[26]. - The gross margin decreased to 64.9%, down 1.1 percentage points from 66.0% in the prior year[26]. - Net profit for the six months was RMB 36,969 thousand, reflecting a 5.3% increase from RMB 35,117 thousand year-on-year[26]. - Revenue from consumer-grade genetic testing services reached RMB 1,044 million for the six months ended June 30, 2024, representing an 83.2% year-over-year increase due to diversified sales channels and product optimization[36]. - Cancer screening services revenue was RMB 29 million for the same period, a 93.1% year-over-year decline attributed to price strategy adjustments and product structure optimization[36]. Operational Efficiency - The company has established partnerships with nearly 1,900 healthcare institutions across over 340 cities in China, with health check centers accounting for approximately 52% of its institutional clients[24]. - The company has developed a comprehensive technology platform that includes multiple testing technologies, enabling it to process up to 50,000 samples daily in its independent testing laboratory[22]. - The company has implemented a lean management approach to continuously optimize its personnel structure and improve operational efficiency[24]. Cash Flow and Financial Position - Net cash generated from operating activities was RMB 150 million, driven by improved collection of accounts receivable[50]. - The company's cash and cash equivalents decreased by 1.8% from RMB 5,183 million as of December 31, 2023, to RMB 5,089 million as of June 30, 2024[50]. - The company's debt-to-asset ratio as of June 30, 2024, was 20.4%, an increase of 1.4 percentage points from 19.0% on December 31, 2023[54]. - The company reported a decrease in trade receivables of RMB 31,822,000 during the reporting period, compared to an increase of RMB 21,347,000 in the same period of 2023[99]. - The company’s total liabilities decreased from RMB 273,169,000 as of December 31, 2023, to RMB 273,169,000 as of June 30, 2024, indicating stability in its financial position[101]. Shareholder Information - The company granted a total of 27,272,000 restricted share units during the reporting period[72]. - The company reported that 9.31% of its shares are held by Dr. Yu Rong through controlled entities, totaling 21,995,135 shares[79]. - Ms. Guo Meiling holds a total of 22,000,000 shares through controlled entities, representing 9.31% of the company's shares[79]. - The company has appointed a new company secretary, Mr. Wu Jiazh, effective June 28, 2024[78]. - The company’s CEO position was temporarily filled by Ms. Jiang Jing following the departure of Mr. Huang Yufeng on January 17, 2024[78]. Compliance and Governance - The company has maintained compliance with corporate governance codes and standards throughout the reporting period[90]. - The group operates a single reportable operating segment, monitoring overall performance without service grouping[104]. - The group has maintained its classification of current and non-current liabilities after reassessing terms and conditions as of January 1, 2024, with no impact on financial position[102].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部 或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 Mega Genomics Limited 美因基因有限公司* （於開曼群島註冊成立的有限公司） （股份代號：6667） 截 至2024年6月30日止六個月的 中期業績公告 美 因 基 因 有 限 公 司（「本公司」）董 事（「董 事」）會（「董事會」）欣 然 宣 佈 本 公 司 及 其 附 屬 公 司（統 稱「本集團」）截 至2024年6月30日 止 六 個 月（「報告期」）的 未 經 審 核 中 期 簡 明綜合業績。 於 本 公 告 中，「我 們」指 本 公 司 及（如 文 義 所 指）本 集 團。本 公 告 所 載 若 干 金 額 及 百 分比數字已作約整。如任何表格的總數與所列數額的總和有任何不符之處，皆為 約整所致。 摘 要 主要財務數據 下表載列我們於截至2024年6月30日止六個月的主要財務數據，連同2023年同期 之 比 較 數 字 及 變 動 情 況（以 百 分 比 或 百 分 點 表 ...

Financial Performance - For the fiscal year ending December 31, 2023, the company recorded a total gross profit of RMB 883 million, representing an 8.0% year-over-year increase[32]. - The gross profit margin for the company was 58.4% for the fiscal year ending December 31, 2023, with the cancer screening service gross margin at 72.1%, an increase of 0.2 percentage points year-over-year[33]. - The gross profit from consumer-grade genetic testing services was RMB 573 million, showing a significant year-over-year increase of 64.4% due to optimized product and service offerings[32]. - For the fiscal year ending December 31, 2023, the company reported revenue of RMB 151.3 million, a 3.8% increase from RMB 145.7 million in 2022[43]. - The company's gross profit for the same period was RMB 88.3 million, with a gross margin of 58.4%, compared to RMB 81.7 million and a gross margin of 56.1% in 2022[66]. - The net profit for the fiscal year was RMB 30.0 million, a significant turnaround from a net loss of RMB 17.6 million in 2022, representing an increase of RMB 47.6 million[52]. - The company reported a gross profit margin of 58.4% for 2023, up from 56.1% in 2022, and a net profit margin of 19.9%, compared to a net loss margin of 12.1% in the previous year[127]. Research and Development - The company plans to enhance its R&D capabilities by recruiting more professionals and collaborating with renowned domestic and international academic and medical institutions[37]. - The company achieved a 15% increase in R&D investment, totaling RMB 22.4 million, with 97 commercialized testing solutions developed during the reporting period[58]. - The company has developed a blood nucleic acid non-extraction technology that effectively saves testing costs and time, with clinical trials involving approximately 1,200 cases expected to complete by the second half of 2024[16]. - The company plans to develop two types of testing kits using qPCR and NGS technologies, with the NGS kit expected to include dozens to hundreds of biomarkers[48]. - The company plans to obtain registration certification for its folate metabolism assessment testing kit in the second half of 2024 after completing clinical trials and submitting for NMPA registration[83]. Sales and Market Strategy - The company collaborated with over 1,800 healthcare institutions across more than 340 cities in China, with health check centers accounting for approximately 54% of the total institutional clients[30]. - The company has established a sales team of over 100 people, expanding its sales network to cover over 340 cities in China[40]. - The company aims to enhance market penetration by collaborating with industry leaders and establishing industry standards through academic conferences and expert collaborations[53]. - Cancer screening service revenue decreased by 34.1% year-over-year to RMB 42.9 million due to adjustments in sales strategy[46]. - The average price for general consumer genetic testing services was RMB 36.4, with a testing volume of 2,973 thousand tests, compared to RMB 48.0 and 1,340 thousand tests in 2022[45]. Operational Efficiency - The company plans to build production laboratories to enhance regional coverage, improve reporting cycles, and reduce operational costs[38]. - The company's administrative expenses increased from RMB 42.9 million in the year ended December 31, 2022, to RMB 44.5 million in 2023, mainly due to increased R&D personnel and related expenditures[94]. - The company's sales and distribution expenses decreased from RMB 34.9 million in the year ended December 31, 2022, to RMB 30.7 million in 2023, reflecting adjustments in sales strategies[93]. - The company's cash and cash equivalents increased by 29.6% from RMB 399.8 million as of December 31, 2022, to RMB 518.3 million as of December 31, 2023[74]. - The net cash generated from operating activities during the reporting period was RMB 163.7 million, significantly improving from a net cash used of RMB 6.9 million in the previous year[101]. Management and Governance - The company has a strong management team with extensive experience in healthcare and business management, enhancing its operational capabilities[184]. - The company has established a robust governance structure with independent directors overseeing strategic decisions[175]. - The management team is focused on leveraging their diverse backgrounds to drive the company's growth and operational efficiency[176]. - The company has undergone significant leadership changes, with Mr. Huang's tenure as a director from December 2020 to January 16, 2024[190]. - Ms. Jiang, the Chief Financial Officer since November 2020, has around 21 years of experience in financial management and will assume CEO responsibilities starting January 17, 2024[169]. Future Outlook - The company plans to utilize the net proceeds from its global offering for various purposes, including sales and marketing (30%), R&D (25%), and operational funding (10%) by June 30, 2025[120]. - The company aims to expand its market presence and enhance its service offerings through strategic planning and investor relations[164]. - The financial report indicates that the company is committed to transparency in its financial activities and will announce any changes in the intended use of proceeds[178]. - The company has no significant acquisitions or disposals of subsidiaries, associates, or joint ventures during the year ended December 31, 2023[130]. - The company has no major events after December 31, 2023, that could significantly impact its operations and financial performance[135].

Mega Genomics Limited 美因基因有限公司* （於開曼群島註冊成立的有限公司） （股份代號：6667） 美 因 基 因 有 限 公 司（「本公司」）董 事（「董 事」）會（「董事會」）欣 然 宣 佈 本 公 司 及 其 附 屬 公 司（統 稱「本集團」）截 至2023年12月31日 止 年 度（「報告期」）的 綜 合 業 績。 主要財務數據 * 僅供識別 下表載列我們於呈列期間所進行的按檢測服務類型劃分的檢測次數及該等檢測 服務的平均價格。 業績回顧 根據弗若斯特沙利文的資料，截至2021年12月31日，按累計已進行檢測量計，我 們為中國最大的消費級基因檢測平台。且按2020年已進行檢測量計，我們是中國 規模最大的癌症篩查基因檢測平台。除文義另有所指外，本公告所用詞彙與本公 司刊發日期為2022年6月10日的招股章程所界定者具有相同涵義。 – 2 – • 營養吸收能力評估檢測套餐－一項評估患高同型半胱氨酸血症風險的服務。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部 或任何部分內容而產生或因倚賴該 ...

Mega Genomics Limited 2023 Interim Report 中期報告 ( 於開曼群島註冊成立的有限公司 ) 股份代號 : 6667 * 僅供識別 2 釋義 6 業務回顧及展望 27 其他資料 33 未經審核中期簡明綜合財務狀況表 36 未經審核中期簡明綜合現金流量表 2023年中期報告 | 02 「董事會」 指 董事會 「本公司」 指 Mega Genomics Limited 美因基因有限公司*，為一家根據開曼群島法律註冊 「COVID-19」 指 2019冠狀病毒病，一種由名為嚴重急性呼吸綜合症冠狀病毒2的新型病毒引 「董事」 指 本公司董事 「本集團」或「我們」 指 本公司及其附屬公司 「香港」 指 中國香港特別行政區 「上市」 指 股份於上市日期在主板上市 「上市規則」 指 香港聯合交易所有限公司證券上市規則 * 僅供識別 | --- | --- | --- | |------------------------|-------|--------------------------------------------------------------------------- ...

31 32 本中期業績公告刊載於聯交所網站 ( www.hkexnews.hk ) 及本公司網站 ( www.megagenomics.cn)。本公司截至2023年6月30日止六個月的中期報告載有 上市規則所規定的所有資料，將於適當時候寄發予本公司股東及刊載於上述網站。 生產設施 收入 9 截至2023年6月30日止六個月，我們錄得綜合毛利為人民幣65.3百萬元，同比增 加1.4%，其中消費級基因檢測服務及癌症篩查服務所產生的毛利分別為人民幣 33.3百萬元及人民幣32.0百萬元，消費級基因檢測服務毛利同比增加41.1%，乃由 於優化產品及服務組合及我們有效控制成本的能力所促使。 前景及展望 根據弗若斯特沙利文，預期從2020年到2030年，中國消費級基因檢測市場的滲透 率將從0.8%增長到11.6%。在這個過程中，更多關於消費級基因檢測行業的行業 標準將逐漸建立，常見疾病的防治指南或專家共識將逐漸形成。我們認為更快速 地推動行業標準的建立至關重要。 與此同時，為了繼續鞏固在消費級基因檢測市場的龍頭優勢，我們不斷升級及推 出新的產品，以滿足龐大的國內消費級基因市場需求。 進一步開發中國癌症篩查檢測市場 我們也 ...

Mega Genomics Limited 美因基因有限公司 * ( 於開曼群島註冊成立的有限公司 ) 股份代號 : 6667 2022 年度報告 僅供識別 | --- | --- | |--------------------------|-------| | | | | 目錄 | | | | | | 釋義 | | | 公司資料 | | | 五年財務概要 | | | 主席報告 | | | 業務回顧及展望 | | | 管理層討論及分析 | | | 董事及高級管理層 | | | 企業管治報告 | | | 環境、社會及管治報告 | | | 董事會報告 | | | 獨立核數師報告 | | | 綜合損益及其他全面收益表 | | | 綜合財務狀況表 | | | 綜合權益變動表 | | | 綜合現金流量表 | | | 財務報表附註 | | 2 6 8 9 10 19 31 38 57 85 120 124 125 127 128 130 釋義 「股東週年大會」 指 本公司於2023年6月9日（星期五）舉行的股東週年大會 「組織章程細則」 指 本公司的組織章程細則（經不時修訂） 「審核委員會」 指 董事會轄下審核委員會 「 ...

Financial Performance - For the year ended December 31, 2022, the total revenue was RMB 145.7 million, a decrease of 38.6% compared to RMB 237.2 million for the year ended December 31, 2021[2]. - The adjusted net profit for 2022 was RMB 2.8 million, representing an adjusted net profit margin of 2.0%, down from 44.4% in 2021[2]. - Revenue for the year ended December 31, 2022, was RMB 145.7 million, a decrease of 38.6% compared to RMB 237.2 million in 2021[100]. - The company recorded a net loss of RMB 17.6 million for the year ended December 31, 2022, compared to a profit of RMB 79.0 million in 2021[163]. - The diluted loss per share for 2022 was RMB (0.09), compared to a profit of RMB 0.62 per share in 2021[183]. - Total equity decreased to RMB 617,997 thousand in 2022 from RMB 694,496 thousand in 2021, reflecting a decline of approximately 11%[187][188]. - Customer contract revenue for 2022 was RMB 145,727 thousand, a significant decrease from RMB 237,185 thousand in 2021, representing a decline of about 39%[199][200]. Revenue Breakdown - Revenue from consumer genetic testing services decreased by 40.5% year-on-year to RMB 80.5 million due to COVID-19 restrictions[131]. - Revenue from cancer screening services decreased by 35.2% year-on-year to RMB 65.2 million, impacted by pricing strategy adjustments and COVID-19[132]. - Revenue from Customer A was RMB 82,057 thousand in 2022, down from RMB 88,336 thousand in 2021[199]. - Customer B's revenue was not applicable in 2022, while it contributed RMB 42,850 thousand in 2021[199]. Cost and Profitability - Gross profit for the same period was RMB 81.7 million, down 51.0% year-over-year, with a gross margin of 56.1%, a decline of 14.2 percentage points[87]. - The gross margin for cancer screening services was 71.9%, a decrease of 3.8 percentage points year-on-year, primarily due to the promotion and pricing strategy adjustments[55]. - The gross margin for consumer-grade genetic testing services was 43.3%, a decrease of 22.9 percentage points year-on-year, attributed to a significant revenue drop while fixed costs remained constant[55]. - Gross profit decreased from RMB 166.7 million in 2021 to RMB 81.7 million in 2022, with gross margin dropping from 70.3% to 56.1%[134]. Research and Development - Research and development expenses increased by 70% compared to 2021, reflecting the company's market-oriented R&D strategy[67]. - Approximately 65% of the R&D team members hold master's degrees or higher from prestigious institutions such as the Chinese Academy of Sciences and New York University[69]. - The company is developing eight in vitro diagnostic (IVD) pipeline products, including Alzheimer's disease screening kits and colorectal cancer screening kits, targeting diseases with high prevalence and lack of effective screening methods[56]. - The company has established a quality management system compliant with IVD registration standards through collaboration with leading CDMO service providers[73]. Product Development and Innovation - The company has developed 91 commercialized testing solutions, with 80 of them being self-developed services[26]. - The company has completed preliminary screening of candidate biomarkers for the gastric cancer screening kit, collaborating with three hospitals and using no less than 1,500 samples for multi-center clinical validation[38]. - The company has developed multiple new risk assessment genetic testing products covering various fields, including cancer risk assessment and cardiovascular diseases[51]. - The company has completed the formulation of the BRCA1/BRCA2 gene mutation detection kit and established a database of tens of thousands of mutation sites[41]. - The company has introduced new products, including the ApoE gene testing kit and folate metabolism assessment testing kit, aimed at assessing risks for Alzheimer's and cardiovascular diseases respectively[15][16]. Market Position and Strategy - The company is recognized as the largest consumer genetic testing platform in China, based on cumulative testing volume as of December 31, 2021[5]. - The consumer-grade genetic testing market penetration in China is expected to grow from 0.8% in 2020 to 11.6% by 2030, indicating significant market potential[80]. - The company plans to launch low-cost home testing screening products, including a fecal occult blood test and transferrin screening, expected to hit the market in 2023[92]. - The company aims to enhance cancer screening penetration, particularly in the colorectal cancer sector, with a focus on improving the sensitivity and specificity of blood methylation screening products[97]. Operational Efficiency - The company has established a comprehensive technology platform, capable of processing 50,000 samples daily, providing cost-effective genetic testing solutions[52]. - Operating costs for sales and distribution increased by 51.7% to RMB 34.9 million in 2022, compared to RMB 23.0 million in 2021[100]. - The company plans to build production laboratories to enhance regional coverage, improve reporting cycles, and reduce operational costs[99]. Financial Health - Cash and cash equivalents increased by 67.2% from RMB 239.1 million as of December 31, 2021, to RMB 399.8 million as of December 31, 2022[122]. - The company has no outstanding loans or similar debts as of December 31, 2022, apart from lease liabilities[148]. - Other income increased by 34.7% from RMB 14.3 million in 2021 to RMB 19.2 million in 2022, mainly due to foreign exchange gains[138]. - Financing activities generated a net cash inflow of RMB 158.5 million, primarily from the company's listing on the stock exchange[146]. Future Plans - The company plans to invest in acquisitions of products with significant market potential or cutting-edge technology to complement its existing product portfolio[93]. - The company plans to expand its R&D capabilities and product matrix while selectively pursuing regional expansion and acquisition opportunities[125][126]. - The company intends to strengthen its R&D capabilities by recruiting more professionals and collaborating with renowned academic and medical institutions[98]. - The company plans to utilize the net proceeds from the global offering for sales and marketing (30%), R&D (25%), testing capabilities and capacity (20%), investments and acquisitions (15%), and working capital (10%)[182].

| --- | --- | --- | --- | --- | |-----------------------------------------------------------------------------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Mega Genomics Limited 美因基因有限公司 * ( 於開曼群島註冊成立的有限公司 ) | | | | | | 股份代號 : 6667 2022 中期報告 | | | | | | --- | --- | --- | --- | --- | --- | --- | |-------|-------|-------|-------|-------|----------------------------------|-------| | | | | | | | | | | | | | | 未經審核中期簡明綜合財務資料附註 | 36 | | | | | | | | | 釋義 「審核委員會」 指 ...